Merck Kills a Last-Resort Antibiotic — and the Economics Behind It

The Quiet Death of a Last-Resort Drug

Merck stopped supplying Recarbrio to the U.S. market earlier this month. The company gave no public explanation. Seven years after FDA approval, a drug designed to treat life-threatening infections in patients with few remaining options has simply vanished from shelves.

Recarbrio is not a blockbuster. It is, by design, a niche antibiotic — a three-drug combination injection reserved for hospital-acquired pneumonia, ventilator-associated infections, and complicated urinary or abdominal infections in patients who have exhausted other treatments. The FDA labeled it a “last-resort” therapy precisely to slow the emergence of antibiotic-resistant superbugs. That label was meant to protect the drug from overuse. Instead, it may have sealed its commercial fate.

The math is unforgiving. Last-resort antibiotics are prescribed sparingly — sometimes to only a few hundred patients annually in the entire United States. At list prices that reflect their developmental cost but cannot scale with volume, they generate revenue that barely covers manufacturing and distribution. Merck did not disclose Recarbrio sales figures in its regulatory filings. The silence is telling.

Why Pharma Walks Away

This is not an isolated incident. It is the logical endpoint of a broken economic model. Antibiotic development has been unprofitable for decades. Companies invest billions in research, clinical trials, and regulatory approval — only to market a drug that doctors are incentivized to withhold until all other options fail.

The conflict is structural. Public health advocates want antibiotics preserved. Prescribers comply. But investors want returns. When a drug’s intended use is deliberately limited, its revenue ceiling is low. Maintenance costs — sterile manufacturing, supply-chain logistics, pharmacovigilance — remain high. The gap between cost and income widens until the product is no longer viable.

Merck’s exit from Recarbrio is a case study. The company invested in a drug that addressed a genuine clinical need — infections caused by multidrug-resistant Gram-negative pathogens, including carbapenem-resistant organisms. The FDA granted priority review. The drug reached patients who had nowhere else to turn. And then Merck walked away.

The decision likely required no dramatic boardroom debate. It was probably a quiet calculation: recurring costs exceed recurring revenue. The patient population is too small. The pricing environment is too constrained. There is no strategic rationale for staying — no companion diagnostic, no expanded indication, no market expansion possible without violating stewardship principles.

What This Means for Patients

The immediate consequence is access. Recarbrio treated infections that other antibiotics could not. Patients with carbapenem-resistant Enterobacteriaceae (CRE), extensively drug-resistant Pseudomonas aeruginosa, or other multidrug-resistant organisms had a therapeutic option. That option is now gone.

Physicians will continue to encounter these infections. The pathogens do not respect product withdrawals. Patients will need alternatives — older antibiotics with narrower spectra, higher toxicity profiles, or uncertain efficacy. Some will receive combination regimens that lack robust clinical evidence. Others may face treatment delays while manufacturers attempt to fill the gap.

The risk is not theoretical. Antibiotic resistance claims hundreds of thousands of deaths annually in the United States alone. Each withdrawal of a last-resort agent narrows the therapeutic arsenal at exactly the moment resistance is accelerating. The paradox is stark: the drugs we need most are the ones companies are least able to keep.

The Bigger Picture

Recarbrio’s discontinuation is a signal. It is not an anomaly — it is a preview of what happens when the economics of antibiotic development remain misaligned with the economics of antibiotic use.

The FDA’s last-resort designation was meant to preserve efficacy. Instead, it created a commercial paradox: a drug whose public-health value is highest is also a drug whose revenue potential is lowest. Companies that invest in such products are rewarded with clinical credibility, not financial returns. Few pharmaceutical firms can sustain that trade-off indefinitely.

Policy responses have been attempted. The 2020 PASTEUR Act proposed pull-through payments — reimburse manufacturers regardless of prescription volume. The 2021 Antibiotic Resistance Biopharmaceutical Acceleration Act sought similar mechanisms. Both have stalled in Congress. The basic problem remains unsolved: society benefits from antibiotics that are used sparingly, but companies cannot profit from antibiotics that are used sparingly.

Other companies have faced similar calculations. Cefideracol, another last-resort antibiotic, faces uncertain commercial viability despite clinical utility. Older agents like colistin and fosfomycin persist because they are cheap to manufacture and difficult to replace — not because they are preferred. The pipeline for new Gram-negative antibiotics is thin. Withdrawals like Recarbrio’s thin it further.

What Happens Next

Merck’s exit from Recarbrio will likely prompt regulatory scrutiny. The FDA monitors drug shortages and availability of critical therapies. Recarbrio qualifies. The agency may seek interim solutions — extending manufacturing licenses, encouraging generic entry, or facilitating alternative suppliers. None of these address the underlying economics.

Other last-resort antibiotics may face similar fates. The pattern is repeatable: a drug is approved for a narrow indication, prescribed sparingly, and eventually withdrawn when revenue cannot justify continued investment. Without structural reform — subscription models, milestone payments, or guaranteed purchase commitments — the cycle will continue.

The public-health implications are severe. Multidrug-resistant infections are not slowing down. CRAB (carbapenem-resistant Acinetobacter baumannii), CRE, and XDR Pseudomonas are spreading in hospitals and communities. Each withdrawal of a last-resort agent reduces the options available to clinicians treating these infections. The gap between clinical need and commercial incentive will widen until something gives.

The Bottom Line

Merck discontinued Recarbrio because the economics do not work. The drug saves lives. It does not make money. The conflict between those two facts is not a flaw in the system — it is the system. Until policymakers align the incentives for antibiotic development with the realities of antibiotic stewardship, companies will keep walking away from the drugs we need most.

The Recarbrio withdrawal is a warning. It is not the last one.